An experimental mRNA vaccine developed by Moderna Inc, combined with Merck & Co immunotherapy, reduced the risk of death or skin cancer recurrence by 44%.
The results of a new study published this Sunday by Reuters suggest that this new vaccine could increase cancer remission time or even life expectancy for patients, researcher Jeffrey Weber said.
“From a therapeutic standpoint, this is a big breakthrough,” said Ryan Sullivan, a melanoma specialist at Mass General Cancer who worked on the study.
The Moderna vaccine is designed to train the immune system to recognize and attack certain mutations in cancer cells.
Approved to treat melanoma and many other types of cancer, Merck & Co’s immunotherapy belongs to a widely used class of immunotherapy known as checkpoint inhibitors, designed to turn off the PD-1 protein that helps cancer escape the immune system.
Among 107 subjects who received both the experimental vaccine and the previously used vaccine, cancer returned in 24 subjects (22.4%) within two years, compared with 20 of 50 (40%) who received immunotherapy alone. Merck & Co.
Author: morning Post
Source: CM Jornal
I am Michael Melvin, an experienced news writer with a passion for uncovering stories and bringing them to the public. I have been working in the news industry for over five years now, and my work has been published on multiple websites. As an author at 24 News Reporters, I cover world section of current events stories that are both informative and captivating to read.